Locally Advanced Pancreatic Cancer Market Report 2026

The locally advanced pancreatic cancer market size has grown rapidly in recent years. It will grow from $1.05 billion in 2025 to $1.16 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to late-stage diagnosis of pancreatic cancer, limited surgical eligibility in locally advanced cases, historical reliance on gemcitabine-based chemotherapy, poor overall survival rates, growing hospital-based oncology care.

The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to expansion of combination therapy protocols, increasing adoption of SBRT, rising investment in pancreatic cancer research, growing focus on personalized oncology care, increasing availability of advanced treatment centers. Major trends in the forecast period include increasing use of combination chemotherapy regimens, growing adoption of neoadjuvant treatment approaches, rising focus on tumor downstaging for surgical eligibility, expansion of radiation therapy in local disease control, growing emphasis on multidisciplinary treatment planning.

The rise in tobacco use is expected to contribute to the growth of the locally advanced pancreatic cancer market in the coming years. Tobacco is a plant whose leaves are utilized in products such as cigarettes and cigars. It contains nicotine, which is addictive and associated with serious health problems, including cancer and heart disease. The increasing use of tobacco is influenced by factors such as easy availability, affordability, marketing by tobacco companies, social acceptance in certain regions, and stress-related smoking. Tobacco consumption is a major risk factor for the development of locally advanced pancreatic cancer, as it leads to a higher incidence of pancreatic malignancies. For example, in October 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported a study on smoking trends among young people, showing a significant increase in smoking rates from 22.5% in 2022 to 40.1% in 2024. Consequently, the growing tobacco use is driving the expansion of the locally advanced pancreatic cancer market.

Major companies operating in the locally advanced pancreatic cancer market are concentrating on developing innovative products, including orphan drugs, to expand treatment options, enhance patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are created to treat rare diseases affecting a small patient population and are incentivized by authorities with benefits such as tax reductions and market exclusivity to encourage their development. For example, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a novel GSK-3β inhibitor, received Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential type of locally advanced pancreatic cancer. This recognition underscores its potential to address a critical gap in treating this severe cancer, particularly after promising Phase 2 trial results demonstrated significant clinical improvements and anti-tumor effects in metastatic PDAC patients.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition is intended to strengthen the oncology portfolio with advanced radiopharmaceuticals such as FPI-2265, enhance research, development, and manufacturing capabilities, and accelerate the transition to targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company actively developing targeted therapies for various cancers, including pancreatic cancer.

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene.

North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the locally advanced pancreatic cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the locally advanced pancreatic cancer market by increasing costs associated with imported oncology drugs, radiation equipment, and specialized medical devices. These effects are more pronounced across chemotherapy and radiation therapy segments, particularly in regions such as asia-pacific and europe that rely on global oncology supply chains. Hospitals and specialty clinics face higher treatment and procurement costs due to tariff pressures. However, tariffs have also encouraged local manufacturing of oncology drugs, regional equipment sourcing, and diversification of supply chains, supporting long-term market stability.

The locally advanced pancreatic cancer market research report is one of a series of new reports that provides locally advanced pancreatic cancer market statistics, including locally advanced pancreatic cancer industry global market size, regional shares, competitors with a locally advanced pancreatic cancer market share, detailed locally advanced pancreatic cancer market segments, market trends and opportunities, and any further data you may need to thrive in the locally advanced pancreatic cancer industry. This locally advanced pancreatic cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Locally advanced pancreatic cancer (LAPC) is a stage of pancreatic cancer in which the tumor is limited to the pancreas and surrounding tissues but has not spread to distant organs. This type of cancer is generally not suitable for surgical removal due to its involvement with major blood vessels or nearby structures.

The treatment options for locally advanced pancreatic cancer include chemotherapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to kill cancer cells or stop their growth. These treatments can be delivered through various methods, such as oral or injectable routes, and are provided in hospitals, specialty clinics, research institutes, and other healthcare settings.

The locally advanced pancreatic cancer market consists of revenues earned by entities by providing services such as chemoradiation, palliative care, targeted therapy, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The locally advanced pancreatic cancer market also includes sales of CT scanners, MRI machines, brachytherapy systems, needle biopsy devices, and hemodynamic monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.